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resumo 
 
 
A disfunção endotelial e as alterações nos processos de regeneração 
endotelial podem desempenhar um papel determinante na patogénese da 
doença cardiovascular, que é uma das principais causas de mortalidade na 
doença renal crónica (DRC). As células endoteliais circulantes (CEC) podem 
ser um indicador de dano vascular, enquanto que as células progenitoras 
endoteliais circulantes (CPEC) pode ser um biomarcador de reparação 
vascular. No entanto, a avaliação simultânea dos níveis de CECs e de CPECs 
e sua relação não foram previamente avaliados numa população de doentes 
renais crónicos. 
Amostras de sangue (18 mL) foram recolhidas a partir de indivíduos saudáveis 
(n = 10), e a partir de doentes renais crónicos em estadios precoces (n=10) e 
em estádios avançados (n=10), para se proceder ao isolamento de populações 
de CPECs imaturas e maduras, CECs e células hematopoiéticas. Estas 
populações de células foram identificadas por citometria de fluxo (sistema BD 
FACS Canto II) usando uma combinação de anticorpos primários conjugados 
com fluorocromos: CD31-PE, CD45-APC Cy7, CD34-FITC, CD117-PerCp 
Cy5.5, CD133-APC, CD309-PE Cy7 e CD146-Paciific blue. Para a exclusão 
das células mortas recorreu-se a um marcador de viabilidade (“fixable viability 
dye”). Este protocolo otimizado de citometria de fluxo de oito cores permitiu 
identificar simultaneamente e com precisão as subpopulações de CECs, 
CPECs e células hematopoiéticas. Além disso, também foi possível distinguir 
as duas subpopulações de CPECs, imaturas e maduras, por marcação 
múltipla CD45intCD31+ CD34+ CD117-CD133+ CD309-CD146- e 
CD45intCD31+ CD34+CD117- CD133-CD309+ CD146-, respetivamente. 
Adicionalmente, a identificação de CECs e células hematopoiéticas foi 
realizada por CD45-CD31+ CD34-/lowCD117- CD133-CD309- CD146+ e 
CD34+ CD117+, respetivamente. 
Os níveis de CECs foram mais elevados em pacientes em estadios precoces 
de DRC (312,1±91,3) e em estadios avançados (191,4±49,9) 
comparativamente com o grupo controlo (103,23±24,13), n.s. Para além disso, 
os níveis de CPECs imaturas foram significativamente diminuídos em estadios 
avançados de DRC (17,1±3,2) em comparação com estadios precoces 
(32,3±4,9), p=0,04, e com o grupo controlo (36,3±6,2), p=0,03. Os níveis de 
CPECs maduras foram significativamente reduzidos em estadios avançados 
de DRC (6,6±1,9), p=0,01 e em estadios precoces (8,4±2,6), p=0,01, em 
comparação com o grupo controlo (91,5±29,1). Estes resultados foram 
acompanhados por uma diminuição acentuada nos índices de capacidade de 
recrutamento, diferenciação e regeneração na população de doentes renais 
crónicos. Globalmente, estes resultados sugerem um desequilíbrio no 
processo de reparação endotelial na DRC, e sugerem ainda, que os índices de 
recrutamento, diferenciação e regeneração podem ajudar na seleção de 
pacientes que possam beneficiar de estratégias de intervenção para melhorar 
a saúde cardiovascular induzindo proteção vascular. 
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abstract 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial dysfunction and impaired endothelial regenerative capacity play a 
key role in the pathogenesis of cardiovascular disease, which is one of the 
major causes of mortality in chronic kidney disease (CKD) patients. Circulating 
endothelial cells (CEC) may be an indicator of vascular damage, while 
circulating endothelial progenitor cells (EPC) may be a biomarker for vascular 
repair. However, the simultaneously evaluation of CEC and EPC circulating 
levels and its relation were not previously examined in CKD population. 
A blood sample (18ml) of healthy subjects (n=10), early CKD (n=10) and 
advanced CKD patients (n=10) was used for the isolation of early and late 
EPCs, CECs, and hematopoietic cells, identified by flow cytometry (BD 
FACSCanto™ II system) using a combination of fluorochrome-conjugated 
primary antibodies: CD31-PE, CD45-APC Cy7, CD34-FITC, CD117-PerCp 
Cy5.5, CD133-APC, CD146-Pacific Blue, and CD309-PECy7. Exclusion of 
dead cells was done according to a fixable viability dye staining. This eight-
color staining flow cytometry optimized protocol allowed us to accurate 
simultaneously identify EPCs, CECs and hematopoietic cells. In addition, it was 
also possible to distinguish the two subpopulations of EPCs, early and late 
EPCs subpopulation, by CD45intCD31+CD34+CD117-CD133+CD309-CD146- 
and CD45intCD31+CD34+CD117-CD133-CD309+CD146- multiple labeling, 
respectively. Moreover, the identification of CECs and hematopoietic cells was 
performed by CD45-CD31+CD34-/lowCD117-CD133-CD309-CD146+ and 
CD34+CD117+, respectively. 
The levels of CECs were non-significantly increased in early CKD (312.06 ± 
91.34) and advanced CKD patients (191.43±49.86) in comparison with control 
group (103.23±24.13). By contrast, the levels of circulating early EPCs were 
significantly reduced in advanced CKD population (17.03±3.23) in comparison 
with early CKD (32.31±4.97), p=0.04 and control group (36.25 ± 6.16), p=0.03. 
In addition the levels of late EPCs were significantly reduced in both advanced 
(6.60±1.89), p=0.01, and early CKD groups (8.42±2.58), p=0.01 compared with 
control group (91.54±29.06). These results were accompanied by a 
dramatically reduction in the recruitment, differentiation and regenerative 
capacity indexes in CKD population. 
Taken together, these results suggest an imbalance in the process of 
endothelial repairment in CKD population, and further propose that the indexes 
of recruitment, differentiation and regenerative capacity of EPCs, may help to 
select the patients to benefit from guiding intervention strategies to improve 
cardiovascular health by inducing vascular protection. 
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1. INTRODUCTION 
 
1.1 Chronic Kidney Disease 
 Chronic Kidney Disease (CKD) is defined as the presence of kidney damage that persists for 
more than 3 months, manifested by abnormal albumin excretion or decreased kidney function, 
quantified by measured or estimated glomerular filtration rate (GFR) (Thomas et al., 2008). It is 
common, frequently unrecognized and often exists together with other conditions (such as 
cardiovascular disease and diabetes). Moderate to severe CKD is also associated with an increased 
risk of other significant adverse outcomes such as acute kidney injury, falls, frailty and mortality. This 
disease is usually asymptomatic, but it is detectable, and tests for CKD are simple and freely available. 
There is evidence that treatment can prevent or delay the progression of CKD, by early detection and 
treatment, reduce or prevent the development of complications, and reduce the risk of cardiovascular 
disease (Levey et al., 2003). To facilitate assessment of CKD severity, the National Kidney Foundation 
developed criteria as part of its Kidney Disease Outcomes Quality Initiative (NKF K/DOQI) to stratify 
CKD patients (Table 1). 
  
Table 1 – Classification of CKD in 5 stages based on the combination of GFR and markers 
of kidney damage, by National Kidney Foundation (Thomas et al., 2008). 
 
 
 
 
 
 
 
  
GFR (mL/min/1,73m2) 
 
Terms 
Stage 1 ≥90 Normal 
Stage 2 60 - 89 Mildly decreased 
Stage 3a 45-59 Moderately to Severely 
decreased Stage 3b 30-44 
Stage 4 15-29 Severely decreased 
Stage 5 <15 Kidney Failure 
2 
 
1.2 Cardiovascular risk in CKD 
 Cardiovascular disease (CVD) is one of the major causes of morbidity and mortality in CKD 
population, 10 to 20 times higher than in general population. Association between CKD and 
cardiovascular complications is linked to a number of factors including traditional risk factors, such as 
age, gender, obesity, hypertension, hyperlipidemia, and nontraditional risk factors typical of CKD like 
uremic toxins, proteinuria, inflammation, alterations of mineral metabolism, and increased oxidative 
stress (Zhang et al., 2014). Cardiovascular morbidity and mortality are inversely and independently 
associated with kidney function, particularly at estimated GFR<15 ml/min per 1.73 m2 (Herzog et al., 
2011).Cardiovascular involvement in CKD can be evaluated by both serological and instrumental tests. 
(Di Lullo et al., 2015). 
 
1.2.1 Endothelial dysfunction in association with CKD 
 Endothelial dysfunction is a condition in which the endothelium (inner lining) of blood vessels 
does not function normally and is observed in CKD patients, sometimes even as early as in stage 1 
(Zhang et al., 2014; Zhang et al., 2014).Increasing documents indicate that prolonged exposure to risk 
factors, such as inflammation and oxidative stress chronically present in CKD patients, may alter the 
normal homeostatic properties of the endothelium and active endothelial cells (De Groot, K. et al, 
2004). It participates in the development of atherosclerosis and could partially explain the high 
incidence of vascular complications in this population (Jourde-Chiche et al., 2009). This manifestation 
of endothelial dysfunction is not only associated with CVD but may also precede its development 
(Endemann & Schiffrin, 2004). Endothelial dysfunction and impaired endothelial regenerative capacity 
play a key role in the pathogenesis of CVD (Hadi et al., 2005). 
 
1.3 Endothelium 
 The endothelium is the monolayer of endothelial cells (Fig. 1) mechanically and metabolically 
strategically located, lining the lumen of the vascular beds and  separating the vascular wall from the 
circulation and the blood components (Lerman & Zeiher, 2005). The healthy endothelium is a major 
player in the control of blood fluidity, platelet aggregation and vascular tone, a major actor in the 
regulation of immunology, inflammation and angiogenesis, and an important metabolizing and an 
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endocrine organ. This organ weighs approximately 1 kg and consists of 1 to-6x 1013 cells. Endothelial 
cells controls vascular tone, and thereby blood flow, by synthesizing and releasing relaxing and 
contracting factors such as nitric oxide (NO), metabolites of arachidonic acid via the cyclooxygenases, 
lipoxygenases and cytochrome P450 pathways, various peptides (endothelin, urotensin, nautriuretic 
peptide type C, adrenomedullin, etc.), angiotensins, prostaglandins, reactive oxygen species (ROS), 
among others. Normally these factors act in a coordinated manner so that the vasodilator and 
vasoconstrictor influences are locally balanced and regulate the resistance of the vascular tone to 
maintain steady tissue perfusion (Kharbanda & Deanfield, 2001). Additionally, these mediators have 
effects on other endothelial functions such as regulation of cell-cell adhesion, thrombosis and 
fibrinolysis. Some of these relaxing and contracting factors will be presented in more detail below. 
 
 
 
 
 
 
 
 
1.3.1 Nitric Oxide 
 Nitric Oxide is an endothelium-derived relaxing factor, generated from L-arginine by the action 
of endothelial NO synthase (eNOS) in the presence of cofactors such as tetrahydrobiopterin (BH4), 
and released in response to stimuli that act on the endothelial cell surface (Davignon & Ganz, 2004). 
Once activated this gas diffuses to the vascular smooth muscle cells and activates guanylate cyclase, 
which reduces intracellular calcium within the smooth muscle cell, causing smooth muscle relaxation 
or vasodilatation (Kharbanda & Deanfield, 2001). Shear stress is a key activator of eNOS in normal 
physiology, besides other signaling molecules that can promote eNOS activation, such as bradykinin, 
adenosine, vascular endothelial growth factor (in response to hypoxia), and serotonin (released during 
platelet aggregation) (Endemann & Schiffrin, 2004). 
Figure 1 – Representation of the healthy endothelium in a human artery.  
(Adapted from http://www.examiner.com/article/prevent-a-heart-attack-tomorrow-mind-your-endothelium-today) 
4 
 
1.3.2 Prostaglandin 
 Prostaglandins are lipid autacoids derived from arachidonic acid. The main prostaglandin 
molecules produced by endothelial cells are prostacyclin (PGI2) and thromboxane A2 (TXA2) (Ricciotti 
& FitzGerald, 2011). PGI2 is a vasodilator that binds to specific receptors on the target cell and 
activates adenylate cyclase to increase cyclic AMP levels, which causes relaxation of smooth muscle. 
On the other hand TXA2 has vasoconstrictor properties and aggregates platelets. Under normal 
physiological conditions the effects of prostacyclin predominate but when this physiology is disturbed 
by disease then vasoconstrictor prostanoids become more important (Kharbanda & Deanfield, 2001). 
 
1.3.3 Endothelin 
 Endothelins are a group of three peptide hormones that have paracrine activity and are potent 
vasoconstrictors. Human endothelial cells secrete endothelin-1 (ET-1), which induce several biological 
effects, such as profound vasoconstriction, pro-inflammatory actions, mitogenic and proliferative 
effects, stimulation of free radical formation and platelet activation (Davignon & Ganz, 2004). In 
addition, ET-1 has been implicated as an important factor in the development of vascular dysfunction 
and cardiovascular disease. Under physiological conditions, ET-1 is produced in small amounts mainly 
in endothelial cells, primarily acting as an autocrine/paracrine mediator, whereas under 
pathophysiological conditions, the production is stimulated in a large number of different cell types, 
including endothelial cells, vascular smooth muscle cells, cardiac myocytes, and inflammatory cells 
such as macrophages and leukocytes (Bohm & Pernow, 2007). 
 
1.3.4 Angiotensin 
 The endothelium modulates vasomotion, not only by releasing vasodilator substances, but 
also by an increase in constrictor tone via generation of endothelin and vasoconstrictor prostanoids, 
as well as via conversion of angiotensin I to angiotensin II at the vessel wall in endothelial surface 
(Deanfield et al., 2007). In turn, Angiotensin II is a peptide that is generated by tissue angiotensin 
converting enzyme (ACE) and has vasoconstrictor, prothrombotic, oxidant and atherogenic properties  
(Endemann & Schiffrin, 2004). 
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1.3.5 Endothelial dysfunction and Circulating Endothelial Cells (CECs) 
 Endothelial dysfunction is also referred as endothelial activation, by some authors, which 
represents a switch from a quiescent phenotype toward one that involves the host defense response 
(Deanfield et al., 2007). In general, cardiovascular risk factors promote endothelial dysfunction, which 
is characterized by reduction of bioavailability and impairment of vasodilator effect of endothelium-
derived relaxing factors, such as NO, prostacyclin or endothelium-derived hyperpolarizing factor 
(Kharbanda & Deanfield, 2001). In addition, can occur an increased production and biological activity 
of the potent vasoconstrictor and pro-inflammatory peptide endothelin (ET-1). The decrease of NO is 
an important factor in this process that results from reduced activity of eNOS, (as a result of 
endogenous or exogenous inhibitors) and to decreased bioavailability of NO (Endemann & Schiffrin, 
2004).This results in an increase of ROS formation (in the presence of superoxide dismutase), lead to 
generation of hydrogen peroxide, which, can diffuse rapidly throughout the cell and react with cysteine 
groups in proteins to alter their function. Moreover, hydrogen peroxide leads to degradation of the 
eNOS cofactor BH4, leading to “uncoupling” of eNOS, and results in superoxide formation. When ROS 
are generated at low concentrations can function as signaling molecules participating in the regulation 
of fundamental cell activities such as cell growth and cell adaptation responses, whereas at higher 
concentrations, results in very different consequences, such as phosphorylation of transcription 
factors, induction of nuclear chromatin remodeling and transcription genes, and protease activation 
(Davignon & Ganz, 2004). In certain circumstances, when exposure to cardiovascular risk factors is 
prolonged and repeated, chronic production of ROS may exceed the capacity of cellular enzymatic 
and nonenzymatic anti-oxidants, as a consequence, the endothelium not only becomes dysfunctional, 
but endothelial cells can also lose integrity, progress to senescence, and detach into the circulation 
(Deanfield et al., 2007). 
 Therefore, the number of circulating endothelial cells (CECs) may reflect the state of 
endothelium dysfunction. Circulating endothelial cells have been recognized as a potential marker of 
endothelial damage in a variety of vascular disorders. A number of antigens have been used to identify 
cells of endothelial origin such as Muc-18 (CD146), Thrombomodulin (CD141), VE-cadherin (CD 144), 
vascular cell adhesion molecule 1 (CD106), Endoglin (CD105), E-selectin (CD62e), intercellular 
adhesion molecule 1 (CD54) and platelet endothelial cell adhesion molecule-1 (CD31) (Zhang et al., 
2014). According to some authors, CECs have high expression for CD34 marker (Kraan et al., 2012). 
In addition mature endothelial cells may express endothelial-specific markers, including type 2 receptor 
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of vascular endothelial growth factor (VEGFR-2), also designated CD309, however they lose this 
marker when beginning the senescence process (Ramcharan et al., 2013). In other hand, these cells 
have negative expression to leukocyte common antigen (CD45) and Prominin 1 (CD133) (Flores-
Nascimento et al., 2015). 
 However, endothelial integrity depends not only on the extent of injury, but also on the 
endogenous capacity for repair. Over time two mechanisms of repair have been identified. One 
through the adjacent mature endothelial cells that can replicate locally, and replace the lost and 
damaged cells, another through the repairment by circulating endothelial progenitor cells (CEPCs) 
(Fig. 2) recruited from the bone marrow. These cells, once in circulation can differentiate into mature 
cells with endothelial characteristics (Zampetaki et al., 2008). 
 
 
 
 
 
 
 
 
1.4 Endothelial Progenitor Cells 
 Endothelial progenitor cells (EPCs) are small, immature precursor and bone marrow derived 
cells that can be found in the peripheral and umbilical cord blood (Burger & Touyz, 2012). They are 
extremely rare events in normal peripheral blood, representing somewhere between 0.01% and 
0.0001% of peripheral mononuclear cells (Khan et al., 2005). These cells were first isolated from adult 
peripheral blood (PB) in 1997 by Asahara and their collaborators using magnetic micro beads, on the 
basis of proteins in cell surface (also known as surface markers); in this case, they based on 
expression of hematopoietic progenitor cell antigen marker (CD34) (Asahara, 1997). With this 
discovery, the dogma that differentiation of mesodermal cells to angioblasts and subsequent 
Figure 2 – Representation of endothelial dysfunction by prolonged ROS signaling, that induces senescence of endothelial 
cells, and the repairment process by adjacent mature endothelial cells and circulating endothelial progenitor cells. (Adapted 
from: Deanfield et al. 2007). 
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endothelial differentiation exclusively occur in embryonic development was overturned, since EPCs 
from adults can differentiate ex vivo to an endothelial phenotype (Urbich & Dimmeler, 2004). In addition 
to the aforementioned markers, EPCs show expression of various endothelial markers in their surface, 
such VE-cadherin (CD144), platelet endothelial cell adhesion molecule-1 (CD31), endothelial NO 
synthase, E-selectin (CD62E) and von Willebrand factor (CD41), show expression of stem cell markers 
such Prominin 1 (CD133), and also express surface markers of Hematopoietic System such c-kit 
(CD117) and Leukocyte Common Antigen (CD45) (Burger & Touyz, 2012) (Yoder, 2012). However, 
no marker was identified as specific for EPCs. 
 Moreover, the mentioned surface markers are dependent on the state and localization of the 
EPCs, because, the surface markers presented in early EPCs are different from the surface markers 
expressed by mature EPCs. The surface markers present in early EPCs are principally CD133, CD34 
and VEGFR-2, termed also kinase insert domain receptor (KDR) or CD309. In the peripheral 
circulation of adults, more mature EPCs are found that obviously have lost CD133 but are positive for 
CD34 and VEGFR-2 (Hristov et al., 2012). It seems, therefore, that the loss of CD133 reflects the 
transformation of circulating EPCs into more mature endothelial-like cells. However, it is not clear at 
which time point the EPCs begin to lose CD133, either during their transmigration from the bone 
marrow into the systemic circulation or later during their mobilization. This indicates that are found two 
types of EPCs in the peripheral blood and that the cells change their progenitor properties in the 
circulation (Urbich & Dimmeler, 2004). 
 
1.4.1 Functions of Endothelial Progenitor Cells 
 Endothelial progenitor cells are involved in physiological neovascularization (new blood vessel 
formation), wound healing, tissue regeneration in ischemia, tissue remodeling and growth of tumors 
(George et al., 2011). To aid in neovasculogenesis, EPCs are mobilized from the bone marrow in 
response to endogenous or exogenous signals and home to peripheral tissue sites to participate in 
endothelial repair. Thus a reduction in EPCs may contribute to the development of endothelial 
dysfunction. (Burger & Touyz, 2012). Endothelial progenitor cells are postulated to arise from an earlier 
progenitor, termed hemangioblast, which also generates hematopoietic stem cells (Urbich & Dimmeler, 
2004). Although EPCs have the same precursor of stem cells, there are differences between these 
two cell populations. 
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 The stem cells are a class of undifferentiated cells that are the remarkable potential to dividing 
and renewing themselves for long periods, and can give rise to specialized cell types. These cells are 
classified as embryonic stem cells (pluripotents) if they are formed during embryological development, 
or as adult stem cells (multipotents), if they are formed in adult tissue. The type of cells that are found 
in bone marrow is the adult stem cells, and can be hematopoietic stem cells (which can produce blood 
cells) and stromal (which can produce fat, cartilage and bone) (Morrison & Scadden, 2014). During 
injuries or neoplastic proliferations, adult stem cells are recruited from the bone marrow and migrate 
to target places to complete self-renewal and differentiation to achieve tissue reconstruction (Zhang et 
al., 2014). Whereas, EPCs derived from multipotent stem cells, are also from bone marrow and are 
able to promote the survival and proliferation of endothelial cells, contribute to vessel formation and/or 
stabilization of new blood vessels. 
 
1.4.1.1 Vasculogenesis and Angiogenesis 
 Neovascularization is an essential mechanism determining the formation, but also the 
maintenance, of the cardiovascular system. It is thought to depend mainly on two processes, 
angiogenesis and vasculogenesis (Fig.3) (Eibel et al., 2011) (Russell, 2013). Angiogenesis is the 
process by which new vessels are formed from pre-existing vessels by the activation, proliferation and 
migration of endothelial cells (ECs). Vasculogenesis is defined as the process by which new vessels 
are generated when there are no pre-existing vessels, by the migration and differentiation of vascular 
endothelial growth factor receptor 2 positive (VEGFR-2+) mesodermal precursors, into ECs that adhere 
to form a primary vascular plexus during embryonic development (Caiado & Dias, 2012). Accumulating 
evidence suggests that EPCs have an important role in homeostasis of the vascular network, when 
vasculogenesis occurs (Yoder, 2012). However, EPCs might not only be involved in the formation of 
new vessels in ischemic tissues, but might also contribute to the repair of pre-existing vessels. Thus, 
EPCs might be interesting candidates for novel therapeutic approaches, such the repair of injured 
vessel wall, the neovascularization or regeneration of ischemic tissue, and the coating of vascular 
grafts (Distler et al., 2009). However, the therapeutic applications of post natal EPCs have a critical 
limitation that is their low number in circulation. 
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1.4.2 Mechanisms by which EPCs improve Neovascularization 
 In the past, the regeneration of injured endothelium has been attributed to the migration and 
proliferation of neighboring endothelial cells. More recent studies, indicate that additional repair 
mechanisms may exist to replace denuded or injured arteries and EPCs are involved in this process 
(Urbich & Dimmeler, 2004). The process from which EPCs mobilize from the bone marrow and 
circulate in peripheral circulation to ischemic tissues and tumors, comprises several steps that are 
recruitment, mobilization, differentiation, homing and regenerative potential of EPCs (Hristov et al., 
2012). 
1.4.2.1 Recruitment 
 Recruitment and incorporation of EPCs requires a coordinated sequence of multistep 
adhesive and paracrine signals termed chemoattraction, which have utmost importance to allow for 
recruitment of reasonable numbers of progenitor cells to the ischemic or injured tissues (Goon et al., 
2006). Those paracrine signals (growth factors or cytokines) generated by ischemic tissue and tumor 
Figure 3 – Representation of angiogenesis and vasculogenesis processes. 
(Adapted from: Eibel et al. 2011). 
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cells include vascular endothelial growth factor (VEGF) and stromal-cell derived factor (SDF-1) 
production. However, additional factors inducing mobilization of progenitor cells from the bone marrow, 
as granulocyte-colony stimulating factor (G-CSF), the granulocyte monocyte-colony stimulating factor 
(GM-CSF), erythropoietin (EPO) and chemokines such SDF-1 also increased the levels of EPCs 
(Aicher et al., 2006). 
 
1.4.2.2 Mobilization and Differentiation 
 Physiologically, ischemia, caused by hypoxia, is believed to be the predominant signal to 
induce mobilization of EPCs from the bone marrow, because hypoxia, in tumors and ischemic tissues, 
mediate activation of hypoxia inducible factor gene (HIF-1) (Ceradini & Gurtner, 2005). 
 This gene is a heterodimeric transcription factor consisting of a β-subunit and an oxygen-
regulated-α-subunit. The HIF-1α and HIF-1β proteins both contain basic helix-loop-helix motifs that 
bind DNA and cause subunit dimerization. This gene, whose activation is prompted by hypoxia 
conditions, can interact with enzymes and other transcription factors in other to control vascularization 
and tissue growth. Therefore, HIF-1 activation promotes an increase synthesis of a potent angiogenic 
factor, termed VEGF, which is a major regulator of angiogenesis, which promotes endothelial cell 
migration toward a hypoxic area. This happens, since during hypoxia, HIF-1 binds the regulatory region 
of the VEGF gene, inducing its transcription and initiating its expression (Ziello et al., 2007). 
 In turn, the expression of VEGF will promote activation of matrix metalloproteinase-9 (MMP-
9) in bone marrow, which will cleave the membrane-bound kit ligand (mKitL) and will induce the release 
of soluble Kit ligand (KitL, also known as stem cell factor, SCF). Subsequently, cKit-positive stem and 
progenitor cells, including also a common hematopoietic and angioblast precursor cells 
(Hemangioblast, HABL), moves to the vascular zone of the bone marrow microenvironment. This 
translocation activates the cells from a quiescent to a proliferative state. The signals, which initiate the 
diversion of the hemangioblast to either hematopoietic precursor cells or EPCs, are largely unknown, 
but may include angiogenic growth factors from the periphery, as VEGF and SDF-1 (Hristov et al., 
2012) (Fig.4). 
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1.4.2.3 Homing and regenerative potential of EPCs 
 It is known that after their differentiation, EPCs leave the bone marrow and move through 
systemic circulation to the ischemic tissues and contact with injured endothelial cells, this process is 
known as homing. It is thought that EPCs mobilization from the bone marrow is mediated by integrins. 
This class of proteins is responsible for cellular tissue architecture and also functions as signal 
transducers regulating survival, proliferation, differentiation and migratory signaling pathways (Caiado 
& Dias, 2012). The main integrins that regulate the mobilization of EPCs from the bone marrow 
microenvironment are the α4 integrins, namely α4β1 and α4β7. The α4β1 integrin mediates cell 
adhesion to vascular cell adhesion molecule-1 (VCAM-1) the α4β7 integrin is important in lymphocyte 
homing and it also binds to VCAM-1 (Chavakis et al., 2005). This data suggests that EPC mobilization 
is an active process involving direct interaction between molecular targets expressed on homing 
tissues and adhesion molecules, namely integrins, expressed by EPCs. The next step of homing of 
progenitor cells to ischemic tissue involves adhesion of these cells to endothelial cells activated by 
cytokines, and the transmigration of the progenitor cells through the endothelial cell monolayer. It is 
known that adhesion of various cells, including hematopoietic stem cells and leukocytes to endothelial 
Figure 4 – Mechanisms by which EPCs are recruited and mobilized from bone marrow to peripheral circulation. 
(Adapted from: Hristov et al. 2012). 
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cells, is also mediated by integrins (Zampetaki et al., 2008). The integrins that are capable to mediate 
cell-cell interactions are the β2-integrins and the α4β1-integrin. The latter are expressed by several 
cell types including endothelial cells and hematopoietic cells, whereas β2-integrins are found 
preferentially on hematopoietic cells. β2-integrins not only mediate the adhesive interactions of EPCs 
to mature endothelial cells and to extracellular matrix proteins but are also critical for chemokine-
induced transendothelial migration of EPCs. During firm adhesion of leukocytes to the endothelium, 
members of the β2-integrin family, interact with endothelial counter ligands such as ICAM-1, VCAM-1, 
and surface-associated fibrinogen (Chavakis et al., 2005) (Fig.5). 
 
 
 
 
 
 
 
 
 
 After adhesion and insertion into the monolayer of surrounding mature vascular ECs, this 
process may be completed, and the injured monolayer is repaired. Thus, EPCs derived from the 
hematopoietic tissue of postnatal bone marrow may possess highly regenerative potential and some 
characteristics of embryonic stem cells (Hristov et al., 2012). 
 
1.4.3 Methods for EPC’s Assessment 
 In 1997, Asahara and their collaborators isolated CD34+ mononuclear blood cells (EPCs) from 
human peripheral blood by means of magnetic beads coated with antibody to CD34 (Asahara 1997) 
.Since this discovery of EPCs, significant steps forward have been taken to reach a better definition 
Figure 5 – Representation of EPCs homing and their adhesion on injured endothelium. 
(Adapted from: Hristov et al. 2012). 
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and a detailed functional characterization of these cells. However, the outcome and success of several 
studies have been limited by the lack of unambiguous and consistent definitions of EPCs (Fadini et 
al., 2008). Actually, there are a variety of procedures that one can use to assist in the isolation and 
quantification of EPCs, but these can be simplified into two approaches: in vitro adhesion and growth 
and selection by cell surface phenotype using fluorescent labeled antibodies or flow cytometry (Hirschi 
et al., 2008). Of note, all current methods for identifying or quantifying the endothelial lineage potential 
of circulating cells have limitations in that none has been shown to reliably predict the behavior of the 
circulating cells in a relevant in vivo context  (Fadini et al., 2008). 
 
1.4.3.1 In Vitro Culture of EPC’s 
 Most culture assays were used to obtain circulating EPCs from peripheral blood for 
identification of EPCs as biomarkers for cardiovascular disease, for analysis of intracellular signaling 
pathways, or for enriching cells for therapeutic angiogenesis (Fadini et al., 2008). After isolation of 
Peripheral Blood Mononuclear Cells, the cells are cultured in medium with specific growth factors (eg, 
VEGF, bovine brain extract, and epidermal growth factor), which facilitates the growth of endothelial-
like cells. The incubation in vitro with a mixture of growth factors, the adhesion of specific substrates 
(eg. Fibronectin), and the contact with the extracellular matrix or the surrounding mature ECs in vivo 
will probably influence the proliferation or differentiation of bone marrow-derived EPCs (Hristov et al., 
2003). The vast majority of studies used one of the following three culture media: Medium 199 (Gibco, 
Carlsbad, California, USA) has been used for the Culture of coloning forming unit (CFU) assay with 
fetal bovine serum only, endothelial growth medium (EGM; Clonetics, San Diego, California, USA) 
supplemented with bovine brain extract and human epidermal growth factor, and EGM-2 (Clonetics, 
San Diego, California, USA) that contains defined concentrations of VEGF-2, human fibroblast growth 
factor 2, human epidermal growth factor, insulin-like growth factor 1, ascorbic acid, heparin and 
hydrocortisone. In addition to different culture media, different extracellular matrix proteins have been 
used for the coating of cell culture dishes, such cell culture dishes coated with collagen, fibronectin or 
gelatin, which might also influence the outcome (Distler et al., 2009). Considering this, through time 
three major methods have been used for EPCs in vitro culture (Fig.6). 
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  Because the proliferative capacity might be one criterion to define a progenitor cell, several 
groups established colony assays (Fadini et al., 2008). The most prominent assay, termed Culture of 
colony forming unit–Hill cells (CFU-Hill), which cells are plated and after 4-9 days, the nonadherent 
peripheral blood mononuclear cells give rise to the colony. In this method all cell populations of the 
PBMC fraction are cultured together, which implies the risk of contamination with mature circulating 
endothelial and monocytic cells. To minimize contamination, some authors included a pre-plating step, 
which the nonadherent cells are removed, based in principle that mature endothelial cells should 
adhere to the culture surface (Hirschi et al., 2008). Another method the Circulating Angiogenic Cells 
(CAC) that consists in culture of adherent mononuclear cells along 4-7 days. In this case, colony 
formation not occurs. Finally, the another method commonly used is termed Endothelial colony forming 
cells (ECFC), which mononuclear cells are plated, and the nonadherent cells are discarded. The 
remaining cells, which are, the adherent cells are cultured along 7-21 days in endothelial conditions, 
and after this time colonies with cobblestone morphology appear. With this method high proliferation 
Figure 6 – Schematic representation of common methods of EPCs in vitro culture. 
(Adapted from: Hirschi, Ingram et al. 2008). 
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capacity was verified. The CFU-Hill and CAC methods present an early outgrowth, whereas ECFC 
method presents a late outgrowth (Hirschi et al., 2008). In addition to the efforts made to improve the 
techniques of EPCs in vitro culture, there will always be a high risk of contamination, and also it has 
been demonstrated that the frequency of EPCs quantified by culture methods does not correlate with 
the number of EPCs quantified by flow cytometry (Hristov et al., 2003). 
 
1.4.3.2 EPCs identification by flow cytometry 
 Flow cytometry is a technique defined as the simultaneous measurement of multiple 
physical characteristics of a single cell as the cell flows in suspension through a measuring device 
(Givan, 2001). This technique allows measurements on cells (prokaryotic and eukaryotic) or particles 
(cytokines, chromosomes and beads) that are in single cell liquid suspension.  
  
 
 
 
 
 
 
 
 
 A flow cytometer is a system consisting of five elements (Fig.7): a light source (mercury lamp 
or laser), a flow chamber, units of optical filters for selecting a range of specific wavelength, the spectral 
range from a more wide, photodiodes or photomultiplier for sensitive detection and signal processing 
with interest and a unit that processes data collected . 
Figure 7 - Representation flow cytometry principles and components. 
(Adapted from: http://www.abdserotec.com/flow-cytometry-signal-processing.html) 
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 In the most common scenario, one or more lasers cross each particle or cell, and the light 
scatter properties are recorded, namely the side scatter (indicator of the particle’s complexity) and 
forward scatter (indicator of the particle’s size) (Givan, 2001). When the laser strikes the cell, the light 
is diffracted around the edges of the cell, producing a diffraction pattern along the path of the laser 
beam. This scattered light (forward scatter and side scatter) is approximately equivalent to the cell 
circumference and is the same wavelength as the exciting laser light. 
The sample cells in suspension can be labeled with specific antibodies linked to 
fluorochromes, which allows the identification and quantification of cells with specific features based 
on the fluorescence (Mund et al., 2012). The fluorochromes emit light when excited by light of a shorter 
wavelength, and can be conjugated directly to the primary or secondary antibody, or to streptavidin. 
The important properties of a fluorochrome are its absorption spectrum, its extinction coefficient at a 
wavelength convenient for excitation, its emission spectrum and its quantum efficiency. The 
fluorochromes conjugated with antibodies are very helpful in flow cytometry technique, some of the 
more widely used fluorescent labels are listed in Table 2. 
 This technique has several advantages, since it allows multiparameter analysis in a large 
number of cells and in short time, allowing the identification of a homogeneous population within a 
heterogeneous population. In addition, also allows the detection of extremely rare populations of 
events (frequencies less than 10-6), such as stem cells, dendritic cells, endothelial cells, among others 
(Bakke, 2001). Flow cytometry is currently the best method to obtain pure quantitative data on putative 
EPCs. Being sensitive, specific and reproducible, should be considered the gold-standard when count 
of peripheral blood EPC is conceived as a disease biomarker (Fadini et al., 2008). In addition, it is a 
rapid and convenient way to measure rare events, thus, this method is clearly well suited for detection 
and quantitation of EPCs. 
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Table 2 - Representation of more widely used fluorochromes in Flow Cytometry, as well their fluorescence 
color, and the wavelength of maximal absorbance and of maximal emission.  
Adapted from: http://www.bdbiosciences.com/reagents/custom_conjugation/index.jsp 
Fluorochrome Fluorescence color Maximal absorbance 
(nm) 
Maximal emission 
(nm) 
AlexaFluorTM405 Blue 401 421 
PacificBlueTM Blue 410 455 
AmCyan Blue 415 500 
AlexaFluorTM488 Green 495 519 
FITC Green 490 525 
PE Yellow 496 578 
APC Red 650 661 
PerCp Red 490 675 
PE-CyTM5 Red 496 667 
PerCP-CyTM5.5 Far Red 496 695 
PECyTM7 Infrared 496 785 
APC-Cy7 Infrared 650 785 
 
 
 Nevertheless, the development of cytometric assays was constrained by the lack of 
reasonably specific monoclonal antibodies for this task (Khan et al., 2005). However, several 
methodologies have been suggested for EPCs identification but there is not a consensual definition 
by cell surface antigen expression. In addition, according to Mund J, some of the clinical trials 
published claiming to quantify EPCs actually quantified hematopoietic stem cells, because they did 
not use enough surface markers (Mund et al., 2012). 
 Delorme, B. et al, proceed to distinction of CECs and EPCs, in samples of cord and peripheral 
blood, based essentially on the surface marker CD146, which is an adhesion molecule present in 
endothelial cells. According these authors, using 4-color flow cytometry analysis, they discriminate 
EPCs (CD146+ CD34+ CD45+CD133+ or CD117+) and CECs (CD146+ CD34+ CD45- CD133- or  
CD117-), in samples of peripheral blood collected from patients after myocardial infarction. As results 
of four color cytometry analysis, the authors obtained, according to CD45 expression, two distinct 
subpopulations of CD34+ cells, respectively CD34+CD45+ cells, representing more than 90% of the 
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circulating CD34+ cells, and CD34+CD45- cells, representing less than 3% of the CD34+ cells. These 
two subpopulations were analyzed individually for the co-expression of CD146, CD117 and CD133, 
among the CD34+CD45+, a low percentage of cells co-expressed the referred surface markers, and 
this subpopulation was defined by authors as EPCs. In turn, the CD34+CD45- subpopulation, co-
expressed CD146 in a higher percentage, but not co-expressed CD117 and CD133. This 
subpopulation defined mature CECs. According these authors, a 4-color cytometry analysis of selected 
CD34+ cells from cord and peripheral blood clearly discriminated between two subsets of circulating 
CD146+ cells (Delorme et al., 2005). 
 On the other hand, Khan, S. and collaborators in their review assume that CD31 and CD146 
are present on CECs but not on EPCs or hematopoietic stem cells, and in addition assume that CD133 
will help to identify EPCs because it is not present on CECs or any mature endothelial cells. However, 
CD133 provided a means for detecting primitive stem cells in the circulation without the use of CD34. 
In addition, according these authors, the CD34+CD309+ combination, is a potential combination of 
surface markers for EPCs identification. Concerning to CD45 expression of these cells, has been 
reported for various groups to be positive or negative, due to its Dim expression (slightly increased 
when compared to the negative control) in these cells (Khan et al., 2005). Some studies suggest that 
particularly the fraction of CD45- cells may harbor the “true” circulating EPCs. For prove this, some 
authors such as Schmidt-Lucke, C. et al, through samples of patients with coronary artery disease 
(CAD), considered, in flow cytometry analysis, the CD45- and CD45dim expression, and in their 
quantification using CD45, CD34 and CD309 surface markers and gating strategy, CD34+ cells were 
subdivided in CD45-, CD45dim and CD45bright. The data obtained with this protocol showed numbers of 
CD45dimCD34+CD309+ cells significantly higher in healthy controls compared to patients with CAD and 
according the authors, this study confirm that indeed only the fraction of CD45dim cells harbours the 
“true” circulating EPCs (Schmidt-Lucke et al., 2010). Another parallel analysis of CD45 expression has 
been also proposed to distinguish EPCs, and most (90%) CD34+ progenitor cells express CD45 at low 
intensity (CD45dim), whereas less than 10% are CD45-(Fadini et al., 2012). Despite this controversy, 
EPCs were assessed by Hristov, M. et al, in the peripheral venous blood of patients with stable 
coronary artery disease by 3-color flow cytometry, by CD34+CD309+CD45-/low combination. As result, 
in flow cytometry analysis, circulating EPCs were obtained in very low percentages, and to improve 
this, the authors recommended additional strategies in order to increase the sensitivity and accuracy 
of the method. These included the use of specific high-quality monoclonal antibodies, selection of high-
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intensity fluorochromes to reveal low-density markers, automatic compensation, exclusion of dead 
cells, and multiparameter gating (Hristov et al., 2012).  
 In other study, EPCs and CECs were quantified in patients with venous thromboembolism and 
myeloproliferative neoplasms, by Torres, C. et al. CECs and EPCs were quantified in peripheral blood 
samples by CD45-CD146+CD133- and CD45+lowCD146+CD133+ immunophenotyping, respectively. 
The chosen strategy used CD146 to recognize CEC, and also to identify EPC and CD133 to distinguish 
between CEC and EPC, since that CD133 is absent in CEC. The results of this study indicate that both 
patients groups had a significant increase in the CEC numbers, as compared to controls, and a 
decrease of EPC numbers (in both patient groups) relatively to controls, although differences were not 
statically significant (Torres et al., 2013). In turn, Rustemeyer, P.et al, through umbilical cord blood, 
bone marrow and whole blood samples, selected the CD309+CD34+ cells, because the EPCs should 
be contained in this fraction. In addition, to exclude a major portion of shredded cells from the vessel 
wall, they measured the number of CD133+CD34+ cells. This fraction showed more CD309+CD34+ 
cells than CD133+CD34+ (Rustemeyer et al., 2006). In other hand, CD133 is expressed on more 
immature cells than CD34 and, for that reason, CD133+CD309+ cells are rarer than CD34+CD309+ 
cells in the circulation, in steady-state conditions (Fadini et al., 2008).  
 Some authors, such as Distler, J. et al defended that EPCs identification requires a multicolor 
approach, that is, the use of several surface markers labeled with fluorochromes. They also 
recommend the use of CD34, CD133 and CD309 to increase the specificity of the analysis (Distler, 
Allanore et al. 2009). In addition, Mund, J. et al, assume that in several studies of EPCs identification 
the contamination with false-positive events and nonspecific fluorescent event readings may occur. 
Specifically monocytes, red blood cells, and dead cells autofluorescence and nonspecifically bind 
antibodies. In his study, trough peripheral blood samples and cord blood samples, a population of cells 
containing endothelial colony-forming cell (ECFCs) and mature circulating endothelial cells was 
determined by varying expressions of CD34, CD31, and CD146, but not CD133 and CD45. The results 
show that if red blood cells, monocytes, and dead/apoptotic (LIVE/DEAD) cells are not excluded, it 
may lead to occurrence of false-positive events (Mund et al., 2012). In review Fadini G., et al, based 
on the definition of EPCs, recommend that the minimal antigenic profile should include at least 1 
marker of stemness/immaturity (usually CD34 and/or CD133), plus at least 1 marker of endothelial 
commitment (usually CD309) (Fadini et al., 2012). 
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 Beyond all controversy, some authors agree in several issues of quality in flow cytometry, 
such as, the use of blocking serum to inhibit nonspecific binding, the use of real-time viability stain, the 
establishment of a dump channel to exclude cells not of interest to analysis, the collection of a large 
number of events to identify adequate numbers of the rare event population, and clean the cytometer 
before data acquisition, to remove amounts of cellular debris that have the potential to contaminate 
the sample of interest. In CEC and EPC assays, at least 500,000 to 1 million list mode events should 
be collected (Khan et al., 2005). In addition, is recommended the setting and monitoring of 
fluorescence detectors sensitivity and the use of a multicolor approach, because no markers are 
entirely specific for these cells (Distler et al., 2009). 
 
1.5 Evaluation of EPCs by flow cytometry in CKD patients 
 Despite the rare nature of EPCs in peripheral blood, several studies identify CKD patients 
taking into account the advantages of EPCs evaluation. Several authors have suggested that EPCs 
are reduced in CKD population. In addition to this decrease, EPCs functions such as migratory activity, 
adhesion to matrix proteins or adhesion to mature endothelial cells are also impaired (Jourde-Chiche 
et al., 2009).  
 In 2003 Einzawa, T, et al, aimed to determine the number and functional activity of EPCs in 
hemodialysis patients and control subjects. In this study the numbers of CD34+ MNC and CD133+ 
MNC in the peripheral blood were quantified using flow cytometry. In results, the numbers of CD34+ 
MNCs and CD133+ MNCs were significantly reduced in hemodialysis patients compared with control 
subjects (Eizawa et al., 2003). 
 On other hand the study of De Groot, K et al, 2004, for explore whether uremia influences the 
number of EPCs, only used CD34 surface marker for assess EPCs in 46 patients with advanced renal 
failure. The results of this study document that the number of EPCs is significantly reduced in patients 
with advanced renal failure as compared with healthy subjects. In conclusion, the authors assumed 
that differentiation of EPCs is inhibited in uremia (de Groot et al., 2004). Moreover, Westerweel, P et 
al, 2007, studied 45 end-stage renal disease patients (ESRD) on hemodialysis, and EPCs are 
identified by CD34+CD309+ using flow cytometry. In this study, levels of circulating EPC were also 
reduced in the peripheral blood of ESRD patients on hemodialysis treatment compared with healthy 
controls (Westerweel et al., 2007). 
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 In turn, Krening, G. et al, 2009, assessed the numbers and the angiogenic function of EPC 
from 50 patients with varying degrees of CKD, considering that in patients with CKD, the number and 
function of EPC may be affected by kidney dysfunction. Mononuclear cells were isolated, and 
circulating EPC were quantified by flow cytometry based on expression of CD14 and CD34. The results 
suggested that the numbers of circulating CD34+ decreased with increasing kidney disease, since was 
observed marked decrease in the number of circulating EPC as early as stage 1 of CKD. In addition 
the results suggested that adherence and endothelial outgrowth of EPC from patients with CKD is 
progressively reduced during kidney disease. In contrast to the reduction in CD34 EPC numbers, there 
was no effect of CKD on the number of circulating CD14 EPC. Therefore, the authors hypothesize that 
the chemoattractants for CD14 EPC and CD34 EPC are differentially expressed in patients with CKD 
(Krenning et al., 2009). However, according to bibliography, CD14 is a monocyte marker, not being 
considered a surface marker of EPCs. 
 Jourde-Chiche, D et al, 2009, studied 38 hemodialysis patients, and after peripheral blood 
mononuclear cells isolation, EPCs were identified by flow cytometry, using CD34+CD133+CD309+ 
labelling. In results, the absolute number of EPCs was reduced in comparison with healthy subjects, 
and the authors concluded that uremic toxins and vascular injury may be among the factors affecting 
EPC numbers in uremia. However, their results suggest that even in a context of reduced EPC 
production induced by uremia, vascular damage may still stimulate EPC release (Jourde-Chiche et al., 
2009). Furthermore, Jie, K et al, 2010, studied 49 patients with different stages of CKD and EPC were 
identified as CD34+CD309+-cells. In results, they observed that CD34+CD309+ levels were lower in 
CKD. In addition, the authors compared EPC levels of CKD patients with a history of CVD and CKD 
patients without a history of CVD. In results CKD patients with a history of CVD showed lower EPCs 
in comparison to other patients. This study shows that pre-dialysis CKD patients on regular medical 
therapy have lower levels of circulating EPC and reduced EPC outgrowth compared to healthy controls 
(Jie et al., 2010). 
 Taken together in all of these studies was observed a reduced number of EPCs, these 
alterations in vascular progenitor cell levels may advance progression of CKD as it has been reported 
that EPC contribute to glomerular endothelial repair (Jie et al., 2010). Therefore, early intervention 
may reduce cardiovascular morbidity in CKD patients through increased physiological vascular 
regeneration (Krenning et al., 2009).  
 
22 
 
  
 23 
 
2. AIM 
 
 Taking into consideration that there is no specific surface marker and there is no an optimized 
protocol for EPCs identification, the main goal of this study was the establishment of a standardized 
protocol for simultaneously identification of EPCs and CECs and their distinction, using a multicolor 
flow cytometry technique. Furthermore in this study we aimed to evaluate the circulating levels of both 
EPCs and CECs, in a CKD population. 
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3. MATHERIAL AND METHODS 
 
3.1 Study Subjects  
 In this study were selected a representative number of CKD patients (n=25) with GFR included 
in stages 1 to 5. Patients were distributed in the 5 stages of CKD according to the glomerular filtration 
rate calculated by MDRD formula (ml/min/1.73m2): Stage 1, > 90; Stage 2, between 60–90; Stage 3 
(comprises 3a and 3b), between 30-59; Stage 4, between 15–29; and Stage 5, < 15. We defined two 
subgroups of CKD patients, the “Early CKD”, with stages comprises between stage 1 and stage 3a, 
and the “Advanced CKD”, with the stages comprises between stage 3b and stage 5. In addition to the 
selected CKD patients, it was selected healthy subjects (n=15), consisting in a control group. 
 Patients with CKD included in several stages and followed-up in the outpatient clinic of 
Nephrology department of “Centro Hospitalar de São João” were invited to participate in the present 
study. The informed consent process and the study protocols were submitted and approved by the 
Ethics Committee of “Centro Hospitalar de São João, EPE” (see Annex 2).  
 
3.2  Isolation of Peripheral Blood Mononuclear Cells 
 Samples of peripheral blood were collected through the antecubital veins to EDTA tubes (0.5M 
EDTA, 3.8% w / v sodium citrate). In the initial step it was collected more volume of blood samples (36 
mL) to flow cytometry optimizations. However this volume of blood was collected from healthy subjects 
for ethical reasons. Taking into account that these cells are extremely rare events, we tried to use the 
greatest amount of blood possible. After these optimizations it was collected a fixed volume of 
peripheral blood samples (18 mL).  
For isolation of mononuclear cells from peripheral blood sample, it  was used the same amount 
of Histopaque-1077 (Sigma-Aldrich, St. Louis, Missouri, United States) and of whole blood sample in 
each falcon (18 mL of blood and 18 mL of Histopaque-1077). In this step it was necessary that the 
blood would be carefully and slowly added in the falcon with Histopaque-1077, which must be on a 
45º inclination. Then, a gradient-density centrifugation was performed during 30 minutes, at 400g and 
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room temperature. Initially, the stipulate centrifugal force would be 800g but a higher layer was at 
400g. After gradient density centrifugation, several layers were observed, as can be seen in Fig.8. 
 
 The mononuclear cells layer was removed carefully by a micropipette to another falcon of 50 
mL, and was resuspended in phosphate buffered saline (PBS) to make up 50 mL and centrifuged for 
10 minutes, at 300g, room temperature. This step was repeated twice, if necessary a second washing. 
 
3.3 Preparation of MNC for flow cytometry staining  
 Afterwards the supernatant was removed and 200 μL of FACS buffer (50 mL PBS, 250 mg 
BSA, 5μL azide) was added and then the mononuclear cells were incubated with FACS buffer in ice 
during 30 minutes to avoid cell aggregation. During this time stained cells with Tripan Blue (Sigma-
Aldrich, St. Louis, Missouri, United States) 1:20, were counted in a Neubauer chamber. One and seven 
millions of cells were counted for the controls and for each mix, respectively, and were transferred to 
a 96 well round bottom ELISA plates (Orange Scientific, Braine-l'Alleud, Belgium). The plate was 
centrifuged during 4 minutes, at 400g, 4ºC. 
 
 
13 mL Histopaque-1077 
Serum and Platelets 
Mononuclear Cells 
Histopaque-1077 
Erythrocytes and 
granulocytes 
Centrifugation 
Figure 8 -– Schematic representation of the blood sample before and after gradient-density centrifugation. 
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3.4 Incubation of MNCs with antibodies 
 After centrifugation, the supernatant was discarded, and the MNC were subsequently labeled 
using the fluorochrome-conjugated primary antibodies CD31-PE (eBioscience, San Diego, USA), 
CD34-FITC (eBioscience, San Diego, USA), CD45-APC Cy7 (eBioscience, San Diego, USA), CD117-
PerCP Cy5.5 (Biolegend, San Diego, California, USA), CD133-APC (Miltenyi Biotec, Bergisch 
Gladbach, Germany) , CD146-eFluor450 (eBioscience, San Diego, USA), CD309-PE Cy7 (Biolegend, 
San Diego, California, USA) (Table 3). In addition, cells were labelled with Fixable viability dye – 
eFluor506 (eBioscience, San Diego, USA), for dead cells exclusion. In Table 3 are represented the 
several antibodies used, associated to fluorochromes and their respective characteristics. 
 
Table 3 - Representation of fluorochromes conjugated with primary antibodies that were used and their maximal 
absorbance and emission wavelength. 
 
 Antibody (Ab) titration was performed in order to determine the optimal amount of Ab for cell 
staining. For all the Abs tested, the optimal concentration was 1µl of antibody per 1 million of cells. 
For staining 7 million of cells, it was scaled up and used 7µl of each antibody for the antibody cocktail 
preparation. For the negative control (unstained) and for FMO control (Fluorescence Minus One- to 
determining positive and negative limits) it was used 1 µL of each Ab to label 1 million of cells. For the 
fixable viability dye, it was used 3.5µl to label 7 million cells. As we wanted to study a rare population, 
Antibody Fluorochrome Fluorescence color Maximal 
absorbance (nm) 
Maximal 
emission (nm) 
CD146 PacificBlueTM Blue 410 455 
Fixable 
Viability Dye 
AmCyan eFluor506 Blue 415 500 
CD34 FITC Green 490 525 
CD31 PE Yellow 496 578 
CD133 APC Red 650 661 
CD117 PerCP-CyTM5.5 Far Red 496 695 
CD309 PECyTM7 Infrared 496 785 
CD45 APC-Cy7 Infrared 650 785 
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in order to spare cells, the automatic compensation settings was done by using UltraCompeBeads 
(eBioscience, San Diego, USA) that bind to the antibodies, with the exception for the viability dye, in 
which were used labeled cells. Briefly, for the UltraCompBeads, we used 1 drop of beads (which 
correspond to 50µL) to label with one specfic antibody; which means a total of 7 drops of beads, each 
one used to be labeled with each of the 7 antibodies used in the staining mix. The table 4 shows the 
constitution of unstained, monolabel controls, FMO controls and Mix, relatively to antibodies and FACS 
buffer. The MNC and the beads with antibodies were incubated during 30 min on ice, protected from 
light. Afterwards they were centrifuged for 4 minutes, at 400g, at temperature of 4ºC. The supernatant 
was discarded and washed twice with 100 μL of FACS buffer, before fixation. The fixation was 
performed with 100 μL paraformaldehyde 4% (Alfa Aesar, Ward Hill, Massachusetts), during 20 
minutes. To remove the excess of paraformaldehyde, 100 μL of PBS were added and cells were 
washed twice by centrifugation for 4 minutes, at 400g, 4ºC. Cells were then stored at 2-8ºC, protected 
from the light, overnight. In the next day, before flow cytometry analysis, it was added 100μL of PBS 
to the samples and then, the cells were filtered with a nylon mesh 1mx1m 100μm (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA), to FACS tubes (VWR International, Radnor, PA, USA) 
(Fig.10). 
 
 
 
 
 
 
 
 
 
 
Membrane Filtration 
FACS tube 
Figure 9 - Schematic representation of methodology used to cells filtration before flow cytometry analysis. 
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Table 4 - Representation of the several conditions used for Flow Cytometric analysis. 
 
 
 
CD45 CD34 CD31 CD117 
 
CD133 CD146 
 
CD309 Viability 
dye 
FACS 
volume 
Unstained Control 
Cells without 
Ab 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
50μl 
Compensation Controls 
Beads+CD45 1 
drop 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Beads+CD34  
- 
1 
drop 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Beads +CD31  
- 
 
- 
 
1 
drop 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Beads+CD117  
- 
 
- 
 
- 
 
1 drop 
 
- 
 
- 
 
- 
 
- 
 
- 
Beads+CD133  
- 
 
- 
 
- 
 
- 
 
1 drop 
 
- 
 
- 
 
- 
 
- 
Beads+CD146 
 
 
- 
 
- 
 
- 
 
- 
 
- 
 
1 drop 
 
- 
 
- 
 
- 
Beads+CD309 
 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
1 drop 
 
- 
 
- 
Cells + Violet 
Dye 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
0.5μL 
 
49.5 μL 
Fluorescence Minus One (FMO) Controls 
FMO- CD45 - 1 μL 1μL 1μL 1μL 1μL 1μL 0.5μL 43.5μL 
FMO- CD34 1μL - 1μL 1μL 1μL 1μL 1μL 0.5μL 43.5μL 
FMO- CD31 1μL 1μL - 1μL 1μL 1μL 1μL 0.5μL 43.5μL 
FMO- CD117 1μL 1μL 1μL - 1μL 1μL 1μL 0.5μL 43.5μL 
FMO- CD133 1μL 1μL 1μL 1μL - 1μL 1μL 0.5μL 43.5 μl 
FMO- CD146 1μL 1μL 1μL 1μL 1μL - 1μL 0.5μL 43.5μL 
FMO- CD309 1μL 1μL 1μL 1μL 1μL 1μL - 0.5μL 43.5μL 
MIX (All Abs) 
Cells + MIX 7 μL 7 μL 7 μL 7 μL 7 μL 7 μL 7 μL 3.5 μL - 
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3.5 Flow cytometry data acquisition and analysis 
 Flow cytometry was performed on a BD FACSCanto™ II system BD Biosciences flow 
cytometer (Becton-Dickenson, New Jersey, U.S.A). The optics of the BD FACSCanto™ II system 
consist of an excitation source with three lasers: blue (488-nm, air-cooled, 20-mW solid state), red 
(633-nm, 17-mW HeNe), and violet (405-nm, 30-mW solid state). The blue laser comprises the 
following detectors, forward scatter (FSC), side scatter (SSC), FITC, PE, PerCp and PECy7, in turn 
the red laser comprise APC and APC Cy7 parameters, while violet laser comprise Pacific blue and 
AmCyan parameters. For EPCs identification it was used all data acquisition parameters of Flow 
cytometer. In first place, the unstained control was acquired for voltages adjustments, and then 
UltraCompeBeads were acquired for automatic compensation.  
 Data analysis was done with FlowJo10 (Treestar, San Carlos, CA) with multiparameter logical 
gating of defined regions. Positive staining and gating strategy was determined by comparison to the 
FMO controls. 
 
3.6 EPC characterization  
  Using the FlowJo10 software, debris such as platelets and other nonspecifically stained events 
were removed based on SSC-A and FSC-A, then dead cells were excluded based on fixable viability 
dye positive expression, and based on FCS-H and FSC-A, the single cells were selected, meaning 
that the doublets and triplets were excluded. For identification of EPCs and ECs, it was tried several 
strategies of gating (see Annex I), until it was identified the optimal strategy.  
 
3.6.1 Strategy adapted from Torres C. et al, 2013 
 As a starting point for our strategy optimization, an analysis based on bibliography (Torres, C. 
et al, 2013) was performed, using only some antibodies (CD45, CD133, CD309, CD146). For EPCs 
identification the strategy used was the following: CD45low > CD133+CD309+ > CD146- cells selection 
(Fig.11.I), and for CECs identification: CD45- > CD309-CD133- > CD146+cells (Fig.11.II). 
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I 
Figure 10 - Representation of gating strategy according Torres et al, 2013. I - EPCs were identified by CD45low cells 
selection, CD133+CD309+ selection, and CD146+ cells selection. II – ECs were identified by CD45- cells selection, CD133-
CD309- and CD146+ cells selection. 
 
II 
I Gated on “Cells” Gated on 
“Single Cells” 
Gated on 
“alive cells” 
Gated on 
CD45low 
Gated on 
CD133+CD309+ 
Gated on “Cells” Gated on 
“Single Cells” 
Gated on 
“alive cells” 
Gated on 
CD45l 
Gated on 
CD133-CD309- 
II 
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3.6.2 Optimized strategy 
 According to the literature, for identification of EPCs there are several strategies that use 
different markers. In addition, there is some controversy between articles relatively to expression of 
some markers by EPCs. However, it does not exist a specific antibody able to identify these rare cells. 
For that we defined a panel that encompasses many of these antibodies that are referred in 
bibliography. Using these antibodies (CD31, CD45, CD34, CD117, CD133, CD309 and CD146) it was 
defined a single strategy that allows to identify two subpopulations of EPCs (early EPCs and late 
EPCs). Early EPCs, immediately after their recruitment from the bone marrow, express specific cell 
marker and with their migration along blood circulation they lose this marker and acquire new surface 
marker, being called late EPCs. For this, it was important the establishment of a single strategy able 
to identify these two subpopulations of EPCs. 
 In addition, the optimized strategy allows to identify a population of circulating ECs and a 
population of hematopoietic progenitor cells that have a common precursor with EPCs. Over the time, 
our strategy has changed in the order of gates, until we achieve the final strategy. 
For early EPCs identification the strategy used was the following: CD45-/intCD31-/+>CD117-
CD34+>CD34+CD133+>CD309-CD146- (Fig.12.II) and for late EPCs identification: CD45-/intCD31-
/+>CD117-CD34+>CD34+CD133->CD309+CD146- (Fig.12.III). For CEC identification the gating 
strategy was the following: CD45-/intCD31-/+>CD117-CD34-/low>CD34-CD133->CD309-CD146+ 
(Fig.12.IV). Taking into account that the putative population of hematopoietic progenitor cells express 
CD34 and CD117 markers in their surface, this subpopulation was identified from  the following gating 
strategy: CD45-/intCD31-/+ >CD34+CD117+ (Fig.12.I). 
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3.7 Statistical experimental design 
 Data are expressed as the mean of the individual values ± standard error of the mean (SEM) 
of values. To analyze mean differences between patient groups and healthy controls, data were 
analyzed using the software’s Microsoft Excel 2010 (Washington, USA) and GraphPad Prism 6 
(California, USA), through the use of T-test or 1 way Anova. A P value <0.05 was considered 
statistically significant.  
Figure 11 - Representation of Gating Strategy for Hematopoietic progenitor cells (I), Early EPCs (II), Late EPCs (III) and CEC (IV) 
identification. 
 
I 
II III 
IV 
Gated on 
“Cells” 
Gated on 
“single cells” 
Gated on “alive cells” 
Gated on 
CD45-/int 
Gated on 
CD117- 
Gated on 
CD34+CD133+ 
Gated on 
CD34+CD133- 
Gated on 
CD34-low 
CD133- 
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 To assess the recruitment, differentiation and the reparative capacity of these subpopulations 
of cells were established three indexes that was obtained using the following formulas: 
 
𝐼𝑛𝑑𝑒𝑥 𝑜𝑓 𝑟𝑒𝑐𝑟𝑢𝑖𝑡𝑚𝑒𝑛𝑡 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 =
number of  "early" EPCs
number of CECs
 
 
𝐼𝑛𝑑𝑒𝑥 𝑜𝑓 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑡𝑖𝑎𝑡𝑖𝑜𝑛 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 =
number of "late" EPCs
number of "early" EPCs
 
 
𝐼𝑛𝑑𝑒𝑥 𝑜𝑓 𝑟𝑒𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑣𝑒 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 =
number of  "late" EPCs
number of CECs
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(A) (B) 
4. RESULTS 
 
4.1 Antibody concentration optimization 
 While establishing the optimal antibodies concentration, we initially observed that with 2 μL of 
antibody to several million of cells (1 until 5 million), the antibodies loss their specificity. Therefore, it 
was necessary an Ab titration. The optimal volume was 1μL of antibody per million of cells, in order to 
avoid non-specific biding. Initially the concentration of fixable viability dye that we used was 1μL, but 
in the first flow cytometry analysis it was observed that numerous cells were marked as dead. 
Therefore, the optimal volume of fixable viability dye was 0.5μL per million of cells. 
 
4.2 EPCs and CECs phenotype 
 The figure12.A refers to the FMO control for CD45 (Leukocyte common antigen marker) 
staining that determines the positive/negative boundaries for this antibody. According to this FMO 
control, we can observe, in figure12.B that most of CD34+ cells (putative EPCs) have intermediate 
expression to CD45 marker and positive expression to CD31.  
 
 
 
 
 
 
 
 
 
 
 
Figure 12 - (A) Dot Plot representing the FMO control for CD45 marker. (B) Dot Plot representing different CD45 expression in 
CD34+ (red color) and CD34- (blue color) cell populations. Gated from “alive cells”. 
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(A) (B) 
 The figure 13.A shows the FMO control for CD34 marker (hematopoietic stem cell marker). 
According to this FMO control, we can observe in figure 13.B that CD309-CD146+ cells (putative CECs 
subpopulation) have both negative and low levels of CD34 expression.  
 
 
 
 
 
 
 
 
 
 
 In figure14 we can observe that all most CD34-/low cells (putative CECs) presented negative 
expression of CD45 and positive expression of CD31. Once that this pattern was reproducible in all 
analysis we selected cells with intermediate and negative expression of CD45 to identify EPCs and 
CECs.  
 
 
 
 
 
 
 
 
 
Figure 13- (A) Dot Plot representing a FMO control for CD34 marker (B) Dot Plot representing CD34 expression in CEC population. 
CD309-CD146+ (blue color) have negative and low CD34 expression. Gated from: “CD45-/int”. 
Figure 14 - Dot Plot representing CD31 and CD45 expression in CEC population (blue color). 
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 Regarding EPCs characterization, with this protocol it was possible to distinguish two different 
subpopulations of EPCs. The figure 15 shows that CD34+CD133+ cells (putative early EPCs 
subpopulation) do not express neither CD146 nor CD309 markers in their surface. Once that this 
results was reproducible in all analysis we selected cells with CD31-/+CD45-/int>CD34+CD117-
>CD34+CD133+>CD309-CD146- to identify early EPCs. Furthermore, we selected cells with CD31-
/+CD45-/int>CD34+CD117->CD34+CD133->CD309+CD146- to identify late EPCs. 
 
 
 
 
 
 
 
 
 
 
 
4.3 EPC characterization 
4.3.1 Strategy adapted from Torres C. et al, 2013 
 In the course of technique optimization, the cytometer voltages have suffered some 
adjustments. The results of this strategy comprised a control group (n=5) and a CKD group (n=5) 
(stages 2 to 5). 
 The results show that EPCs levels were decreased in CKD patients group (0.3±0.1 cell/mL) 
in comparison with control group (2.3±0.8 cells/mL), without statistical significance (Fig.16.A), 
whereas, the levels of ECs were increased in CKD patients (185.5±76.2 cell/mL) in comparison with 
the control group (1.8±0.8 cells/mL), also without statistical significance (Fig.16.B). However, the index 
of regenerative capacity was significantly lower in CKD patients group (0.007 ± 0.03) than in control 
group (3.9±1.5), p=0.008 (Fig.17). 
Figure 15 - Dot Plot representing early EPCs expression for CD309 and CD146 markers. 
Gated from CD34+CD133+ cells. 
CD34+CD133+ 
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Figure 16 - Levels of EPCs (A) and CECs (B) among CKD patients (n=5) and control subjects (n=5). 
(A) (B) 
Figure 17 – Levels of ratio EPC/CEC among CKD patients (n=5) and control subjects (n=5).  
**P<0.01 compared with control group. 
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4.3.2 Optimized strategy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(C) 
Figure 18 - Levels of early EPCs (A), late EPCs (B), hematopoietic progenitor cells (C) and CECs (D) among early CKD 
(n=10) and advanced CKD (n=10) patients and control subjects (n=10).  
*P<0.05 compared with control group. †P<0.05 compared with Early CKD group. 
 
*† 
(A) (B) 
(D) (C) 
 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 – Levels of Index of recruitment capacity (A), Index of differentiation capacity (B) and Index of regenerative 
capacity (C), among early CKD (n=10) and Advanced CKD (n=10) patients and control group (n=10). *P<0.05, 
**P<0.005 compared with control group. 
(A) 
(B) 
(C) 
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 The results shows that the levels of early EPCs (Fig.18.A) were significantly lower in advanced 
CKD group (17.0±3.2 cells/mL) compared with early CKD group (32.3±4.9 cells/mL), p=0.04, and 
control group (36.3±6.2 cells/mL), p=0.03, and the levels of late EPCs (Fig.18.B) were significantly 
lower in both advanced CKD (6.6±1.9 cells/mL), p=0.01, and early CKD groups (8.4±2.6 cells/mL), 
p=0.01, than in control group (91.5±29.1 cells/mL). By contrast, the levels of CECs (Fig.18.D) were 
higher in early CKD group (312.1 ± 91.3 cells/mL) than in advanced CKD (191.4 ± 49.9 cells/mL) and 
control group (103.2 ± 24.1 cells/mL), without reaching statistical significance. The levels of 
hematopoietic progenitor cells (Fig.18.C) was higher in advanced CKD group (37.9 ± 8.7 cells/mL) 
and in early CKD group (33.3 ± 6.4 cells/mL) than in control group (24.5 ± 3.3 cells/mL), however 
without reaching statistical significance. 
 The ratio between early EPCs and CECs (Fig.19.A) is considerable reduced in both early CKD 
(0.3 ± 0.1) and advanced CKD groups (0.3 ± 0.1) in comparison with control group (1.6 ± 0.7), however 
the values did not achieve statistical significance. In addition the ratio between late EPCs and early 
EPCs (Fig.19.B) is significantly reduced in both early CKD (0.4 ± 0.1), p=0.0045, and advanced CKD 
groups (0.6 ± 0.3), p=0.04, in comparison with control group (1.9 ± 0.4). Moreover, the ratio between 
late EPCs and CECs (Fig.19.C) is also considerable reduced in both early CKD (0.04 ± 0.02) and 
advanced CKD groups (0.2 ± 0.1) in comparison with control group (4.5 ± 2.1), but the values did not 
achieve statistical significance.  
 Table 5 represents the percentages (%) of hematopoietic progenitor cells, early EPCs, late 
EPCs and ECs in relation with the total number of MNCs in all studied groups. The % of hematopoietic, 
early EPCs and late EPCs subpopulations ranged between 0.01 and 0.07%, while the % of CECs 
subpopulation ranged between 0.11 and 0.26%. 
 The percentage of late EPCs subpopulation was significantly lower in both early and advanced 
CKD groups compared with control group. By contrast, the percentage of CECs subpopulation was 
significantly higher in advanced CKD group compared with in control group. 
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Table 5 - Representation of percentages values obtained to hematopoietic progenitor cells, early EPCs, late 
EPCs and CEC, in a total of mononuclear cells. *P<0.05; **P<0.01 compared with group control, n=10. 
 
 
4.4 Evaluation of EPCs by flow cytometry in CKD population 
 In the Introduction section several works are cited referring the use of different strategies and 
combinations of markers for EPCs identification by flow cytometry. In order to compare our results with 
these strategies, we tested different combinations of markers, in early (n=10) and advanced CKD 
(n=10) patients and in control subjects (n=10). In table 6 are present the results that were obtained for 
each strategy, according to the literature.  
Taking account only CD34 expression used by De Groot, K et al, 2004 and Asahara et al, 1997, 
our results show a non-significant decrease in the levels of these cells only in advanced CKD group 
compared with the control group. Using only CD133 marker used by Eizawa, Murakami et al. 2003, 
the levels of cells were slight increased in early CKD in comparison with control group, without reach 
statistical significance. Relatively to CD34+CD309+ strategy used by Peter E. Westerweel et al. 2006, 
the levels of these cells were non-significantly lower in early CKD group than in control group. Finally, 
using the CD34+CD309+CD133+ strategy, used by Jourde-Chiche, Dou et al. 2009, the levels of these 
cells obtained were also non-significantly lower in early CKD than in control group. 
 
 Control Group Early CKD Advanced CKD 
Hematopoietic 
progenitor cells 
0.04 % 0.04% 0.04% 
Early EPCs 0.03% 0.03% 0.02% 
Late EPCs 0.07% 0.01%** 0.01%** 
CECs 0.11% 0.24% 0.26%* 
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Table 6 - Representation of different strategies for EPCs identification and the number of cells/mL obtained in 
each strategy in early CKD, advanced CKD and control group. 
Strategy for EPCs 
identification 
Authors Control Group 
(cells/mL) 
Early CKD 
(cells/mL) 
Advanced CKD 
(cells/mL) 
 
CD34+ 
de Groot et al., 2004 
Asahara, 1997 
 
200.5±31.1 
 
195.5±37.8 
 
165.6±33.8 
 
CD133+ 
Eizawa et al., 2003  
33.4±3.7 
 
54.5±9.5 
 
39.3±8.7 
 
CD34+CD309+ 
Westerweel et al., 
2007 
 
27.0±5.7 
 
21.7±4.2 
 
25.9±6.7 
 
CD34+CD309+CD133+ 
Jourde-Chiche et 
al., 2009 
 
3.5±0.8 
 
1.7±0.2 
 
3.0±0.9 
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5. DISCUSSION 
 
 Circulating endothelial cells are released to the blood circulation after vascular injury, while 
EPCs are recruited from bone marrow and mobilized to damage sites to perform vascular repair. Which 
means that CECs and EPCs have been considered as biomarkers of endothelial injury and endothelial 
repair, respectively (Zhang et al., 2014). However, the identification and quantification of CECs and 
EPCs in the blood is technically very difficult and not yet well standardized (Khan et al., 2005). 
Therefore, the present thesis was designed to develop an optimized protocol of flow cytometry for 
accurately and simultaneously identification of EPCs and CECs in the same blood sample.  
 To date, the most commonly used methods for EPCs identification were adhesion and growth 
in vitro; and selection by cell surface phenotype using fluorescent labeled antibodies by flow cytometry 
(Hirschi et al., 2008). However the culture assay requires a large blood sample and a long assay time. 
Whereas, flow cytometry technique offers the promise of a highly sensitive, accurate and reproducible 
approach. In addition this technique allows exactly identification and enumeration of rare and complex 
cell subpopulations, including overlapping phenotypes (Fadini et al., 2008). One of the major problems 
resides in the correct marker combination for EPCs identification. Based on literature, there are several 
strategies for EPCs identification, but the most common combination of markers is based on surface 
expression of CD34 and CD309 (Westerweel et al., 2007) (Jourde-Chiche et al., 2009), as 
hematopoietic marker and adhesion marker, respectively. However, there is some controversy and 
doubts regarding the expression of some surface markers of EPCs. Taking account the several surface 
markers that are referred in the current literature, it was defined in our work a panel that encompasses 
many of these antibodies. Therefore, in our study, EPCs and CECs were simultaneously identified 
based on the differential expression of CD45, CD31, CD34, CD117, CD133, CD146 and CD309.  
 Regarding to the optimization of the flow cytometric protocol and because of the low 
percentage of analyzed circulating cells, additional strategies were applied in order to increase the 
sensivity and accuracy of our assay. This included the selection of high-intensity fluorochromes (PE, 
APC, PE-Cy7) to reveal low-density markers (CD31, CD133, CD309), and the selection of low-intensity 
fluorochromes (FITC, PerCp-Cy5.5, APC-Cy7, Pacific blue) to reveal high-density markers (CD34, 
CD117, CD45, CD146). In addition, was performed automatic compensation, exclusion of dead cells 
and doublets, and multiparameter gating. For setting gates and determining positive and negative 
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limits, were used FMO controls. With these adjustments it was possible to demonstrate, in the present 
study, that all the fraction of CD34+ cells that may harbor the true circulating EPCs, have consistently 
intermediate expression of CD45 and positive expression to CD31, contradictorily to the literature 
(Delorme et al., 2005) (Torres et al., 2013) (Fadini et al., 2008). Additionally, it was possible to 
demonstrate that all the fraction of CD34+CD133+ cells (putative early EPCs subpopulation) do not yet 
express adhesion markers such as VEGFR2 (CD309), also in contradiction to what was described in 
the literature (Hristov et al., 2003). Therefore, we defined a gating strategy able to distinguish early 
EPCs subpopulation phenotypically identified as CD31+CD45intCD117-CD34+CD133+CD309-CD146- 
cells, and late EPCs subpopulation phenotypically identified as CD31+CD45intCD117-CD34+CD133-
CD309+CD146- cells. Moreover, with a different gating strategy it was possible also to identify CECs 
(CD31-/+CD45-/intCD117-CD34-/lowCD133-CD309-CD146+) as well as hematopoietic progenitor cells 
that have the same precursor of EPCs (CD34+CD117+), using the same panel of antibodies in the 
same peripheral blood sample (see Fig.20). To the best of our knowledge, this is the first report in 
which early and late EPCs, CECs and hematopoietic progenitor cells were simultaneously quantified. 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 – Schematic representation of EPCs mobilization from bone marrow in cases of vascular damage, as well the 
phenotype of the different subpopulations identified (early EPCs, late EPCs, CEC). 
The present thesis also aimed to evaluate the influence of kidney function in the circulating 
levels of both EPCs and CECs, in a CKD population. Despite EPCs and CECs have been already 
identified in other diseases, such as in patients with myocardial infarction (Delorme et al., 2005), 
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venous thromboembolism and myeloproliferative neoplasms (Torres et al., 2013) and colorectal 
cancer (Ramcharan et al., 2013), the present work is the first to identify and distinguish EPCs and 
CECs in CKD patients.  
 In this study, is presented for the first time an assay that allows the distinction and 
quantification of different subpopulations of circulating progenitor cells. Globally, the results show a 
drastically reduction in EPCs levels accompanied by a slight increase in CECs levels in CKD patients 
compared with control subjects, according to the literature (Jourde-Chiche et al., 2009). In healthy 
individuals there is a balance between EPCs and CECs levels reflecting a preservation of endothelium 
integrity and homeostasis. This balance is disrupted in CKD patients. The increased levels of CECs 
found in CKD patients are indicative of an endothelial dysfunction status characteristically observed in 
this population. On the other hand, the levels of early EPCs subpopulation were significantly reduced 
in advanced CKD group compared with controls, whereas the levels of late EPCs subpopulation were 
significantly reduced in both advanced and early CKD patients in comparison with control group. These 
results were accompanied by a dramatically reduction in the recruitment, differentiation and 
regenerative capacity indexes in CKD population, indicating a disruption in endothelial repairment 
process in these patients. 
 Our findings suggest that in CKD patients the differentiation step is more impaired than the 
recruitment step (see Fig.21), once that the levels of early EPCs subpopulation were higher than late 
EPCs. Excessive oxidative stress, which is known to be related to increased cardiovascular risk in 
CKD associated with injured vascular endothelium, may inhibit the differentiation of early EPC into late 
EPC, contributing to the compromised reparative mechanisms in this population (Toshio Imanishi, 
2003). EPCs represent a promising therapeutic approach that may contribute to treatment of 
cardiovascular disease in CKD patients. Early intervention and an improvement of the EPCs 
differentiation step may reduce cardiovascular morbidity in CKD patients through increased 
physiological vascular. 
 Early CKD patients presented higher levels of CECs in circulation than advanced CKD group, 
which was not accompanied by a significant reduction in early EPCs levels, suggesting a 
compensatory recruitment of this subpopulation of cells. Several studies have reported, in these 
patients an increasing of VEGF production associated with endothelial dysfunction status that 
mediates not only the proliferation of endothelial cells but may also stimulate the recruitment of EPCs 
from bone marrow (Zampetaki et al., 2008). 
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 In the present work are presented some strategies described in the literature in order to 
compare with the results obtained by our eight-color staining flow cytometry optimized protocol. The 
strategies were based only in the expression of one, two or three surface markers that may be not 
enough to accurate identify EPCs, and could also causes false positive values, making it difficult to 
compare data. Despite the different combinations of markers, all works of EPCs identification in CKD 
population have reported a reduction of EPCs numbers in patients with advanced CKD as compared 
with healthy subjects. To explain the results, some authors assumed that differentiation of EPCs is 
inhibited, whereas other authors suggested that adherence of EPCs is impaired in CKD (De Groot, K 
et al, 2004) (Krenning et al., 2009).  
 In summary, multicolor flow cytometry can abruptly increase the discriminatory power of cell 
analysis, which is very important to identify rare events as EPCs. In that context, a fast, simultaneous 
analysis of EPCs and CECs may substantially contribute to a coherent, prognostic, and diagnostic 
definition to the monitoring of vascular homeostasis. Taking account the main goal, our optimized flow 
cytometric protocol can be effectively applied as the basis for a standardized, sensitive and current 
technique in clinical studies, namely in CKD population. Moreover, our data demonstrate that EPCs 
are numerically and functionally impaired in CKD patients. Therefore, the results presented here 
reinforce the use of EPCs and CECs as vascular biomarkers. Our results further reinforce the potential 
Figure 21 – Representation of the differences between early and advanced CKD in EPCs 
mobilization steps (recruitment, differentiation and regenerative capacity).  
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value of the established indexes as a useful indicator of recruitment, differentiation and endothelial 
regenerative capacity. These indexes could help to select the patients to benefit from guiding 
intervention strategies to improve cardiovascular health by inducing vascular protection.  
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6. CONCLUSIONS 
 
What is new? 
 The development of an eight-color staining flow cytometry optimized protocol to accurately 
and simultaneously identify EPCs, CECs and hematopoietic progenitor cells; 
 The distinction of two subpopulations of EPCs (early and late EPCs) in the same sample; 
 The establishment of three indexes indicatives of recruitment, differentiation, and regenerative 
capacity of these cells. 
 
And now? 
 Increase the number of patients in different stages of CKD as well as control subjects. 
 Develop a personalizing analysis appropriate to each patient, once that it was verify 
physiological differences between patients; 
 Using in vitro colony-forming assays to confirm the phenotype of the subpopulations of 
circulating cells that were identified by flow cytometry technique. 
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8. ANNEXES 
Annex 1: Different strategies used until strategy optimization 
  Strategy 1 
 In the strategy 1 were used all antibodies. After excluding debris, dead cells, doublets and 
triplets, we gated on CD117+CD34+, and within this gate we selected the CD31-CD45- cells, and within 
this population we checked for CD133+CD309+ cells and CD146-cells for EPCs identification (Fig. 1.I). 
For CECs identification, the gating hierarchy was: CD117-CD34- > CD31+CD45- > CD133-CD309+ > 
CD146+ cells selection (Fig. 1.II).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
II 
Figure 1 – Representation of first strategy of analysis.  I – Enumeration of EPCs was performed by CD117+CD34+ selection, 
CD31-CD45- selection, CD133+CD309+ selection, and finally selection of CD146-cells. II – Enumeration of ECs was performed by 
CD117-CD34- selection, CD31+CD45- selection, CD133-CD309+ selection, and CD146+ cells selection. 
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The results obtained with this strategy shows that EPCs are lower in CKD patients (0.15±0.02 
cell/mL) than in control group (0.39±0.14 cell/mL), (Fig.2.A). The absolute number of ECs was lower 
in CKD patients group (1.53±0.68 cell/mL) than in control group (1.92±0.55 cell/mL), p=0.75 (Fig.2.B). 
The index of regenerative capacity (Fig.2.C) was lower in CKD patients (0.23±0.06 cell/mL) than in 
control group (0,42 ± 0,13), p=0.37. 
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Figure 2 – Levels of EPCs (A), ECs (B) and of ratio EPC/CEC (C) among CKD patients (n=5) and control subjects (n=5). 
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 Strategy 2 
 
 For EPCs identification were selected the CD45- and intermediate (int) cells and CD31-/+ cells, 
then were selected CD34+CD133+, CD309+CD146-, and finally were selected CD117+ cells (Fig.3.I). 
For ECs identification were selected the same cells CD45-/int CD31-/+, CD34-CD133-, CD309+CD146+ 
and finally were selected CD117- cells (Fig.3.II). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Representation of Strategy 2 of analysis. I - EPCs were identified by CD45-/int CD31-/+ cells, CD34+CD133+, 
CD309+CD146-, and CD117+ cells. II – ECs were identified by CD45-/int CD31-/+ cells, CD34-CD133-, CD309+CD146+ 
and CD117- cells. 
I 
II 
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 The results obtained with this strategy shows that EPCs are significantly lower in advanced 
CKD (0.25±0.07 cell/mL) compared with control group (0.47±0.08 cell/mL), p=0.035. The levels of 
EPCs were also lower in early CKD (0.13±0.05 cell/mL) compared with control group, although it is 
not significant (p=0.06) (Fig.4.A). The levels of ECs were lower in Advanced CKD (0.27±0.06 cell/mL) 
in comparison with early CKD (16.86±11.31 cell/mL) (p=0.17), and in control group (2.35±0.92 
cell/mL) (p=0.16) (Fig.4.B) The index of regenerative capacity was significantly higher in advanced 
CKD (1.16±0.33 cell/mL) than in early CKD patients (0.06±0.02 cell/mL) (p=0.13) but was lower than 
control group (1.17±0.50 cell/mL) (p=0.99) (Fig.4.C). 
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Figure 4 – Levels of EPCs (A), ECs (B) and of Ratio EPC/CEC (C) among early CKD (n=3) and late CKD (n=5) patients and 
control subjects (n=7).  *P<0.05 compared with control group. †P<0.05 compared with early CKD group. 
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 Strategy 3 
 For early EPCs identification were selected CD45-/intCD31-/+, CD117-CD34-/+, CD34+CD133+ 
and CD309-CD146- (Fig.5.II). For late EPCs identification were selected CD45-/intCD31-/+, CD117-
CD34-/+, CD34+CD133- and CD309+CD146- (Fig.5.III). For ECs identification were selected CD45-
/intCD31-/+, CD117-CD34-/+, CD34-CD133- and CD309+CD146+ (Fig.5.IV). Taking into account that 
Hematopoietic progenitor cells express CD34 and CD117 markers in their surface, this subpopulation 
is identified from CD45-/intCD31-/+ gate (Fig. 5.I). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
II 
III 
IV 
Figure 5 – Representation of Strategy 3 of analysis. I – Hematopoietic progenitor cells were identified by CD45-/int CD31-/+ cells, 
CD34+CD117+. II- Early EPCs were identified by CD45-/int CD31-/+ cells, CD34-/+ CD117-, CD34+CD133+, CD309-CD146-. III – Late EPCs 
were identified by CD45-/int CD31-/+ cells, CD34-/+CD117-, CD34+CD133-, CD309+CD146- cells. IV – ECs were identified by CD45-/int CD31-/+ 
cells, CD34-/+CD117-, CD34-CD133-, CD309+CD146+. 
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Figure 6 – Levels of Hematopoietic progenitor cells (A), early (B) and late EPCs (C), ECs (D), Ratio early EPCs/CECs (E), Ratio 
late EPCs/CECs (F) and Ratio early EPCs/late EPCs (G), among early CKD (n=10) and Advanced CKD (n=10) patients and control 
group (n=10). *P<0.05 compared with control group. †P<0.05 compared with Early CKD group. 
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 The results shows that the levels of hematopoietic progenitor cells were higher in advanced 
CKD (37.94 ± 8.73 cell/mL) and in early CKD (33.32 ± 6.39 cell/mL) than in control group (24.52 ± 
3.28 cell/mL) (Fig.6.A). The levels of early EPCs were significantly lower in advanced CKD 
(17.03±3.23) compared with early CKD (32.31±4.97 cell/mL), p=0.04, and Control group (36.25±6.16 
cell/mL), p=0.03 (Fig.6.B). The numbers of late EPCs were significantly lower in advanced CKD 
(6.60±1.89 cell/mL), p=0.01, and in early CKD (8.42±2.58 cell/mL), p=0.01, than control group 
(91.54±29.06 cell/mL) (Fig.6.C). The numbers of ECs were higher in advanced CKD (5.82±1.99 
cell/mL) than early CKD (4.65±1.34 cell/mL) and control group (4.67± 0.94 cell/mL) (Fig.6.D). 
 The ratio among early EPCs and ECs was decreased in advanced CKD (6.82 ± 1.49 cell/mL) 
and early CKD (9.06 ± 2.42 cell/mL) in comparison with control group (13.20 ± 3.56 cell/mL) (Fig.6.E) 
and the ratio among late EPCs and ECs was also decreased in advanced CKD (2.02±0.66 cell/mL) 
and in early CKD (2.68±1.15 cell/mL) in comparison with control group (33.23 cell/mL) (Fig.6.F). In 
turn, the ratio early EPCs/late EPCs was significantly increased in advanced CKD (12.82 ± 3.94 
cell/mL) in comparison with control group (0.78 ± 0.16 cell/mL), the levels of early CKD (17.88± 5.82 
cell/mL) were also increased in comparison with Control group, but it is not significant (Fig.6.G). 
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Annex 2: Informed consent process and study protocols approved by the ethics 
committee of “Centro Hospitalar de São João, EPE”. 
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Annex 3: Scientific Production  
 Poster presentation in Congress I3S 4th Annual Meeting 2014, realized in “Hotel AXIS 
VERMAR” on 30-31 October 2014. 
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 Poster presentation in symposium Winter Science Club 2014, realized in “Biblioteca Almeida 
Garret” on 19 December 2014. 
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 ePoster presentation in Encontro Renal 2015 XXIX Congresso Português de Nefrologia, XXIX 
Congresso APEDT, VII Congresso Luso-Brasileiro de Nefrologia, realized in Vilamoura on 15-
18 de Março. 
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 Poster presentation in. 52nd ERA-EDTA Congress, realized in London on 28-31 May.  
 
 
 
